Celebrating 20 Years of IP Excellence

px Novo Nordisk.svg

A Patently Generic Win

This post was first published on April 23, 2012. In a landmark decision on a generic drug-maker’s ability to introduce a generic drug for uses not indicated on the branded product’s label, the US Supreme Court ruled in favour of Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries, in its patent litigation against Novo Nordisk over Caraco’s generic version of Prandin, repaglinide tablets, a blood glucose lowering drug. The drug in question, Prandin, generically known as repaglinide, is used…

Read more